Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors (NCT01851200)
The purpose of the study is to assess the activity of brentuximab vedotin (also known as SGN-035) in refractory germ cell tumors.
This trial is sponsored by Fondazione Michelangelo. 
- Condition: Germ Cell Tumors
- Phase: II
- Estimated Enrollment: 9
- Start: May 2013
- Estimated Completion: June 2015
- Last verified: January 2015
Last Editorial review: July 11, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.